A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Trial Profile

A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-1
  • Sponsors AbbVie
  • Most Recent Events

    • 09 May 2017 Results assessing efficacy and safety, presented at the Digestive Disease Week 2017
    • 08 May 2017 Results from this trial were presented at the The International Liver Congress (ILC) 2017, according to an Enanta Pharmaceuticals media release.
    • 08 May 2017 Primary endpoint (Percentage of Participants with Sustained Virologic Response 12 weeks After Treatment) has been met, according to an Enanta Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top